Innocan Pharma Corporation announce that a new patent application has been filed for Innocan's CBD Delivery System Technology, alongside the existing LTP (CBD Loaded Liposomes) and CLX (CBD Loaded Exosomes). The new patent application discloses a unique and novel delivery system allowing the controlled release of CBD into the blood stream with improved pharmacokinetic (PK) performance. This patent application is a significant milestone in the research conducted in collaboration with the Hebrew University, that indicates the potential of the Company's technological ability to deliver cannabinoids to the blood stream in precise and effective administration. The Company believes that the continuous exposure to CBD in blood for a longer time post local administration, seems to be superior to orally administered CBD in two aspects: (a) it will all allow a single administration of CBD instead of daily administration; and (b) it will overcome the low (10%-20%) oral bioavailability of CBD. The superior PK of the CBD Delivery System administered, may achieve controlled concentration of CBD in the blood leading to a better clinical outcome.